KINGDOM THERAPEUTICS HOLDINGS LIMITED

Overview

Kingdom Therapeutics Holdings Limited is a clinical-stage biotechnology company based in Ireland, focused on research into the gut-brain-endocannabinoid axis, particularly in relation to autism spectrum disorder (ASD). The company is developing KT-20610, a drug candidate aimed at improving both behavioural and gastrointestinal symptoms in individuals with ASD. It has completed a positive pre-IND meeting with the FDA and has partnered with Novotech for clinical trial support. The name suggests a focus on pharmaceutical development, cannabinoid science, and neurodevelopmental treatments. The company operates in the pharmaceuticals and biotechnology sector, with a clear emphasis on autism and gut-brain health. Information from its newsroom and scientific focus indicates active development and regulatory engagement. Beyond registry-level identification, no further business details are publicly captured.

Location & registered address

Quaybaun

Caragh Lake

Foley Street

Killorglin

Kerry

Ireland

Industry classification

NACE Rev. 2 — 64.20

→ All NACE 64.20 companies in Ireland · In Kerry